Allergy Therapeutics PLC Total Voting Rights (2980V)
2023年12月1日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMAGY
RNS Number : 2980V
Allergy Therapeutics PLC
01 December 2023
Al l er gy Therapeu tics p lc
(" A l l ergy Ther apeut ics", the "Group" or "C o mpany ")
Total Voting Rights
1 December 2023 Allergy Therapeutics plc (AIM: AGY) announces
that pursuant to its block admission facility, it has recently
issued 4,928,544 ordinary shares of 0.1 pence each in the capital
of the company ("Ordinary Shares") in satisfaction of the exercise
of share options. The new Ordinary Shares rank pari passu with the
Company's existing shares.
In accordance with DTR 5.6.1 of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, as at 30
November 2023, the Company has 4,763,874,771 Ordinary Shares in
issue. There are no shares held in treasury. The total number of
voting rights in the Company is therefore 4,763,874,771.
The above figure of 4,763,874,771 may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Panmure Gordon (Rule 3 Adviser, Nominated Adviser and
Broker)
Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0)20 7886 2500
ICR Consilium
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company, headquartered in the UK, focussed on the
treatment and diagnosis of allergic disorders, including aluminium
free immunotherapy vaccines that have the potential to cure
disease. The Group sells proprietary and third-party products from
its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad
pipeline of products in clinical development includes vaccines for
grass, tree, house dust mite and peanut. For more information,
please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAPFEDFKDFFA
(END) Dow Jones Newswires
December 01, 2023 02:00 ET (07:00 GMT)
Allergy Therapeutics (LSE:AGY)
過去 株価チャート
から 4 2024 まで 5 2024
Allergy Therapeutics (LSE:AGY)
過去 株価チャート
から 5 2023 まで 5 2024